Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Public ClinicalTrials.gov record NCT03221426. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
Study identification
- NCT ID
- NCT03221426
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 1,007 participants
Conditions and interventions
Conditions
Interventions
- 5-fluorouracil Drug
- Capecitabine Drug
- Cisplatin Drug
- Docetaxel Drug
- Leucovorin Drug
- Oxaliplatin Drug
- Pembrolizumab Biological
- Placebo Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 8, 2017
- Primary completion
- Feb 15, 2024
- Completion
- Apr 22, 2025
- Last update posted
- Mar 8, 2026
2017 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope ( Site 0005) | Duarte | California | 91010 | — |
| Yale Cancer Center ( Site 0016) | New Haven | Connecticut | 06520 | — |
| Georgetown University ( Site 0015) | Washington D.C. | District of Columbia | 20007 | — |
| Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0018) | Chicago | Illinois | 60611 | — |
| The University of Chicago Medical Center ( Site 0004) | Chicago | Illinois | 60637 | — |
| Roswell Park Cancer Institute ( Site 0001) | Buffalo | New York | 14263 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0019) | New York | New York | 10016 | — |
| Memorial Sloan Kettering ( Site 0024) | New York | New York | 10065 | — |
| Weill Cornell Medical Center ( Site 0023) | New York | New York | 10065 | — |
| University of Rochester ( Site 0011) | Rochester | New York | 14642 | — |
| Fox Chase Cancer Center ( Site 0006) | Philadelphia | Pennsylvania | 19111 | — |
| Temple University Hospital ( Site 0026) | Philadelphia | Pennsylvania | 19140 | — |
| University of Utah, Huntsman Cancer Institute ( Site 0012) | Salt Lake City | Utah | 84112 | — |
| Virginia Cancer Specialists, PC ( Site 0010) | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 157 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03221426, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03221426 live on ClinicalTrials.gov.